慢阻肺月报202409-1
文摘
科学
2024-09-25 23:21
上海
![]()
Chest. 2024 Aug 26; PMID: 39197510Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine Reduces Exacerbation Rate and Risk in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease.Frank C Sciurba, Stephanie A Christenson, Tara Rheault, et al![]()
Lancet Respiratory Medicine. 2024 Sep 6; PMID: 39265600Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial.Irene J Higginson, Sarah T Brown, Adejoke O Oluyase, et al![]()
American Journal of Respiratory and Critical Care Medicine. 2024 Aug 30; PMID: 39213002Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in COPD: A Post-hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS).Dave Singh, Fernando J Martinez, John R Hurst, et al![]()
Chest. 2024 Aug 23; PMID: 39182575Phosphodiesterase-5 Inhibitor Treatment is Associated with Improved Survival in Pulmonary Hypertension Associated with COPD in the PVRI GoDeep Meta-Registry.Khodr Tello, Athiththan Yogeswaran, Raphael W Majeed, et. Al![]()
